Belgium-based molecular diagnostics firm Biocartis Group has introduced a new in-vitro diagnostic device (IVD) called Idylla NRAS mutation test to detect metastatic colorectal cancer (mCRC).

The new IVD test can detect 18 NRAS mutations from a single slice of FFPE tumour tissue within two hours with a hands-on time of fewer than two minutes.

Performed on the firm’s Idylla system, the CE-marked test can qualitatively detect the NRAS mutations in codons 12, 13, 59, 61, 117 and 146 of the NRAS oncogene.

It releases DNA from the FFPE tissue of human colorectal cancer to enable real-time polymerase chain reaction (PCR) amplification and detection.

Biocartis chief commercial officer Hilde Eylenbosch said: "The launch of the Idylla NRAS mutation test as a CE-marked IVD test demonstrates we are on top of our customer demands.

"It further completes our colorectal cancer test offering on Idylla, that is today already one of the most advanced, rapid and easy-to-use molecular diagnostic test offerings on the market."

“This NRAS test for colorectal cancer patients will respond to existing market needs of both laboratories and hospitals on the one hand, and our pharmaceutical partners on the other hand, in geographies where BRAF testing for metastatic colorectal cancer (mCRC) patients is not reimbursed.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Additionally, it further completes our colorectal cancer test offering on Idylla, that is today already one of the most advanced, rapid and easy-to-use molecular diagnostic test offerings on the market."

According to data from a clinical validation study, the test demonstrated a 99.6% of overall agreement for NRAS oncogene mutations, when compared to a sequencing-based reference method.

The firm’s portfolio of colorectal cancer tests now includes three CE-marked solid biopsy tests, which can detect a total of 44 mutations directly from a slice of FFPE tumour each, and two research-only liquid biopsy assays that can together identify 46 mutations directly from 1ml of blood plasma each.